Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons 1 Top Analyst Gives a Thumbs-Down to Tilray

By Keith Speights – Updated Apr 12, 2019 at 8:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Tilray looks like an underperformer in the eyes of one analyst. Is he right?

Tilray (TLRY) ranked as the best Canadian marijuana stock by far in 2018. It's been a different story this year, though. And one analyst thinks Tilray will probably continue to lag behind its peers in 2019.

Investment firm Jefferies initiated coverage of Tilray last week with an "underperform" rating. Analyst Owen Bennett doesn't think that Tilray stacks up well against rivals Canopy Growth (CGC -1.80%) and Aurora Cannabis (ACB -2.40%). There were three specific reasons Jefferies gave a thumbs-down to Tilray.

A man gives a thumbs-down sign.

Image source: Getty Images.

1. Uninspiring approach to the recreational pot market

Bennett wrote to Jefferies clients that he doesn't think Tilray's approach to the Canadian recreational marijuana is "as well thought through" as Aurora's and Canopy's. So what is Tilray's approach to this market?

The company has signed supply agreements with seven of Canada's 10 provinces and two territories. Tilray is also in negotiations with two other provinces. That's not too far behind what Aurora and Canopy have accomplished. The company also has 10 brands targeted for the recreational pot market in Canada.

Tilray thinks its data licensing agreement with cannabis website Leafly will give it insight into the brands and products that Canadians prefer. This relationship apparently didn't move the needle for Bennett, though. 

In particular, Bennett doesn't think Tilray is well positioned for the cannabis derivatives market. Tilray did land a deal in December with Anheuser-Busch InBev to research nonalcoholic beverages containing tetrahydrocannabinol and cannabidiol (CBD). However, investors pretty much yawned when the partnership was announced because it was narrow in scope and didn't involve an investment in Tilray by the giant beermaker.

Check out the latest earnings call transcript for Tilray.

2. Limited production capacity

Bennett also singled out Tilray's production capacity. The company doesn't talk much about its capacity in terms of kilograms of cannabis that can be produced. However, Tilray has been quick to point out that it has 912,000 square feet of growing space.

But that square footage is a lot less than what either Aurora Cannabis or Canopy Growth have. Tilray at present probably can't even produce 100,000 kilograms of cannabis per year. A company can only make money from what it sells, so Bennett is right that production capacity is a limiting factor for Tilray's growth prospects.

It should be noted, though, that Tilray is beefing up its capacity. The company acquired Natura Naturals Holdings in February. The deal gives Tilray a 662,000-square-foot greenhouse facility, although currently only 155,000 square feet are licensed for production. In addition, Tilray has plenty of land available to construct new facilities. 

3. Unimpressive positioning for U.S. market

Bennett wrote to Jefferies clients that Tilray's "optionality in the U.S. is less impressive" than Canopy's and Aurora's. What did he mean by that statement?

It's likely that Bennett was comparing Tilray more to Canopy Growth than to Aurora Cannabis. While none of the companies can enter the U.S. marijuana market and retain their listings on major stock exchanges because marijuana remains illegal at the federal level, hemp is now legal in the United States.

Canopy Growth is investing between $100 million and $150 million in a major hemp production facility in New York state. So far, though, Aurora hasn't done anything to expand into the U.S. Bennett seemingly wasn't enthusiastic about Tilray's decision to acquire Manitoba Harvest, the largest hemp food company in the world, which already markets hemp CBD products at major retailers in the U.S. and Canada.

Piling on

Jefferies isn't the only naysayer when it comes to Tilray. The stock has a much higher level of short interest than either Aurora Cannabis or Canopy Growth does. 

My view is that much of the criticism of Tilray is fair. The stock's valuation certainly appears to be steep for Tilray's production capacity. On the other hand, Tilray has a strong management team that has made some pretty good deals, in my view. I suspect that the company is better positioned for the global market, including the U.S., than Owen Bennett suggests.

I think there are definitely better marijuana stocks than Tilray. But I wouldn't bet the farm against its success over the long run.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Anheuser-Busch InBev. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.22 (-2.40%) $0.03
Canopy Growth Stock Quote
Canopy Growth
CGC
$2.73 (-1.80%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.